Rev-erbα agonist GSK4112 treatment in primary human lung fibroblasts and IPF lung tissue explant cultures have been shown to reduce TGFβ1-induced activation of ECM genes Acta2 and Col1a1 [9]. This evidence concerns the gene TGFB1 and idiopathic pulmonary fibrosis.